Oncology Drug Reference Sheet: Relugolix
Chelsea Backler MSN, APRN, AGCNS-BC, AOCNS®
Voice
Description
On December 18, 2020, the U.S. Food and Drug Administration (FDA) approved relugolix (OrgovyxTM) as the first oral hormone therapy for use in adult patients with advanced prostate cancer.
ONS Drug Education
Short summaries of newly approved oncology-related therapies or drugs with new indications.
View All Drug Education